Synapsoft logo
AI Insights from Disclosures
Searching...
Amicogen, Inc. 092040
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
Amicogen, Inc., since its establishment on May 29, 2000, has focused on the development and commercialization of various special enzymes for pharmaceutical use, including the CX enzyme needed to manufacture the cephalosporin antibiotic raw material 7-ACA, based on its self-developed molecular gene evolution technology. The company is an industrial bio specialist that has expanded its special enzyme technology into healthcare materials (N-acetylglucosamine, D-chiro-inositol and pinitol, collagen peptide, and collagen tripeptide), a brand business (K-NUTRA), and biopharmaceutical materials (Protein A resin, culture media, and others). Based on its gene evolution technology and metabolic engineering technology, the company has succeeded in commercializing the CX enzyme.
Representative Director Pyo Jjeo
Founded May 29, 2000
Corporation Type KOSDAQ
Industry Classification Manufacture of prepared animal feeds and feed additives
Corporate number 19111-0019783
Business number 613-81-21213
Phone Number 055-759-6161
Fax Number 0557596977
Company Address 14-10 Worasan-ro 950beon-gil, Munsan-eup, Jinju-si, Gyeongsangnam-do
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant